WO1998036067A9 - Proteines secretees et polynucleotides les codant - Google Patents
Proteines secretees et polynucleotides les codantInfo
- Publication number
- WO1998036067A9 WO1998036067A9 PCT/US1998/002767 US9802767W WO9836067A9 WO 1998036067 A9 WO1998036067 A9 WO 1998036067A9 US 9802767 W US9802767 W US 9802767W WO 9836067 A9 WO9836067 A9 WO 9836067A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polynucleotide
- seq
- protein
- amino acid
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Definitions
- the present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.
- the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
- SEQ ID NO:6 The predicted amino acid sequence of the BK34_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6. Additional nucleotide sequence from the 3' portion of BK34_3/ including the polyA tail, is reported in SEQ ID NO:7.
- CT24_3 The nucleotide sequence of CT24_3 as presently determined is reported in SEQ ID NO:14. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CT24_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:15. Amino acids 10 to 22 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23, or are a transmembrane domain.
- the invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous, or related to that encoded by the polynucleotides .
- polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below.
- Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).
- the polynucleotides provided by the present invention can be used by the research community for various purposes.
- the polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip” or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques;
- infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis.
- a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.
- up regulation or enhancement of antigen function may be useful in the induction of tumor immunity.
- Tumor cells e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma
- a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides.
- Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic ceUs that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol.
- Assays for embryonic stem ceU differentiation include, without limitation, those described in: Johansson et al. CeUular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood
- a protein of the invention may also exhibit one or more of the foUowing additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or caricadic cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting
- the amount of protein of the present invention in the pharmaceutical composition of the present invention wUl depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further.
- ATTATCCTGT ATTCCTTTGG CTTGGCATCT TTTAGCTCAG GAAGGTAGAA GAGATCTGTG 1560
Abstract
L'invention concerne de nouveaux polynucléotides et les protéines qui sont codées par ces polynucléotides.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98906384A EP0981612A2 (fr) | 1997-02-14 | 1998-02-13 | Proteines secretees et polynucleotides les codant |
| AU61622/98A AU6162298A (en) | 1997-02-14 | 1998-02-13 | Secreted proteins and polynucleotides encoding them |
| CA002280968A CA2280968A1 (fr) | 1997-02-14 | 1998-02-13 | Proteines secretees et polynucleotides les codant |
| JP53592498A JP2002514070A (ja) | 1997-02-14 | 1998-02-13 | 分泌タンパク質およびそれをコードするポリヌクレオチド |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80041897A | 1997-02-14 | 1997-02-14 | |
| US08/800,418 | 1997-02-14 | ||
| US2269298A | 1998-02-12 | 1998-02-12 | |
| US09/022,692 | 1998-02-12 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1998036067A2 WO1998036067A2 (fr) | 1998-08-20 |
| WO1998036067A3 WO1998036067A3 (fr) | 1999-01-14 |
| WO1998036067A9 true WO1998036067A9 (fr) | 1999-02-18 |
Family
ID=26696248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1998/002767 Ceased WO1998036067A2 (fr) | 1997-02-14 | 1998-02-13 | Proteines secretees et polynucleotides les codant |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0981612A2 (fr) |
| JP (1) | JP2002514070A (fr) |
| CA (1) | CA2280968A1 (fr) |
| WO (1) | WO1998036067A2 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1117793A2 (fr) * | 1998-10-01 | 2001-07-25 | ZymoGenetics, Inc. | Proteine secretoire 48 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5536637A (en) * | 1993-04-07 | 1996-07-16 | Genetics Institute, Inc. | Method of screening for cDNA encoding novel secreted mammalian proteins in yeast |
| US5707829A (en) * | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
-
1998
- 1998-02-13 CA CA002280968A patent/CA2280968A1/fr not_active Abandoned
- 1998-02-13 EP EP98906384A patent/EP0981612A2/fr not_active Withdrawn
- 1998-02-13 WO PCT/US1998/002767 patent/WO1998036067A2/fr not_active Ceased
- 1998-02-13 JP JP53592498A patent/JP2002514070A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2269755A1 (fr) | Proteines secretees et polynucleotides codant ces proteines | |
| EP0977853A1 (fr) | Proteines secretees et polynucleotides les codant | |
| CA2274732A1 (fr) | Proteines secretees et polynucleotides codant pour lesdites proteines | |
| EP0971950A2 (fr) | Proteines secretees et polynucleotides les codant | |
| CA2278770A1 (fr) | Proteines secretees et polynucleotides les codant | |
| WO1997046682A2 (fr) | Polynucleotides issus des proteines secretees par l'adultes humains et codant pour les pbmc | |
| WO1999007840A1 (fr) | Proteines secretees et polynucleotides les codant | |
| EP1062233A1 (fr) | Proteines secretees et polynucleotides les codant | |
| EP0996721A2 (fr) | Proteines secretees et polynucleotides les codant | |
| EP0972026A2 (fr) | Proteines secretees et polynucleotides codant ces proteines | |
| CA2273845A1 (fr) | Proteines secretees et polynucleotides les codant | |
| EP0968287A2 (fr) | Proteines secretees et polynucleotides codant pour celles-ci | |
| EP1007660A2 (fr) | Proteines secretees et polynucleotides les codant | |
| EP1032594A1 (fr) | Proteines secretees et polynucleotides les codant | |
| WO1998036067A9 (fr) | Proteines secretees et polynucleotides les codant | |
| WO1998036067A2 (fr) | Proteines secretees et polynucleotides les codant | |
| EP1032652A1 (fr) | Proteines secretees et polynucleotides codant ces proteines | |
| WO1999047555A1 (fr) | Proteines secretees et polynucleotides les codant | |
| WO1998030584A2 (fr) | Proteines secretees et polynucleotides les codant | |
| EP1002072A1 (fr) | Semaphorine e d'origine humaine et polynucleotides codant cette semaphorine e | |
| EP0939805A2 (fr) | Proteines secretees et polynucleotides codant pour celles-ci | |
| EP1044220A1 (fr) | Proteines secretees et polynucleotides les codant | |
| CA2309007A1 (fr) | Proteines secretees et polynucleotides les codant | |
| CA2295212A1 (fr) | Proteines secretees et polynucleotides codant ces proteines | |
| EP0915971A2 (fr) | Polynucleotides issus des proteines secretees par l'adultes humains et codant pour les pbmc |